Company research / WINT

Windtree Therapeutics Inc (WINT)

SEC name WINDTREE THERAPEUTICS INC /DE/ · CIK 0000946486 · OTC · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

Key ratios (year ended 2024-12-31)

-17.9%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-07-22

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2025-09-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-14, first reflected in a filing dated 2016-03-29; 1-for-50, first reflected in a filing dated 2023-03-31; 1-for-18, first reflected in a filing dated 2024-05-15. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2025-09-30
2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenuen/an/an/an/an/an/a$198.0K$1.79M$1.49M$2.04M$987.0K
Cost of Revenuen/an/an/an/an/an/an/an/an/an/a$929.0K
Gross Profit (computed)n/an/an/an/an/an/an/an/an/an/a$58.0K
R&D Expense$8.54M$16.28M$8.34M$11.10M$17.79M$15.37M$12.69M$10.56M$17.38M$31.70M$28.89M
Operating Income-$33.50M-$26.14M-$20.60M-$41.33M-$77.28M-$30.32M-$24.89M-$16.20M-$22.55M-$38.04M-$39.83M
Depreciation & Amortizationn/an/an/an/an/an/an/an/a$192.0K$255.0K$712.0K
EBITDAn/an/an/an/an/an/an/an/a-$22.36M-$37.78M-$39.12M
Net Income-$39.99M-$1.79M-$20.29M-$39.21M-$67.64M-$32.57M-$27.48M-$20.53M-$18.45M-$39.49M-$55.17M
EPS (Diluted)n/an/an/an/an/an/an/a-$7.74-$24.14-$4.74-$7.98
Total Assets$15.98M$27.88M$32.41M$37.95M$74.79M$112.89M$118.97M$119.40M$3.35M$9.70M$44.38M
Total Liabilities$27.58M$14.70M$29.02M$27.94M$32.91M$43.33M$44.04M$51.28M$27.27M$38.53M$36.11M
Shareholders' Equity-$11.61M$10.00M$3.39M$10.01M$41.88M$69.55M$74.94M$68.11M-$23.92M-$28.83M$8.27M
Cash & Equivalents$204.0K$1.78M$4.32M$6.17M$22.35M$16.93M$22.58M$11.19M$1.81M$5.59M$38.72M
Operating Cash Flow-$15.12M-$15.40M-$13.44M-$19.45M-$23.66M-$25.32M-$24.66M-$15.78M-$21.05M-$33.59M-$33.50M
Capital Expenditures$0$12.0K$15.0K$13.0K$279.0K$291.0K$191.0Kn/a$24.0K$281.0K$458.0K
Free Cash Flow-$15.12M-$15.41M-$13.45M-$19.46M-$23.94M-$25.61M-$24.85Mn/a-$21.07M-$33.87M-$33.96M
Dividends Paid$400.0K$657.0K$0n/an/an/an/an/an/an/an/a
Shares Outstanding33.63M256.4K6.7K772.2K565.4K16.92M13.70M32.13M3.23M436.2K8.19M
Weighted Average Diluted Sharesn/an/an/an/an/an/an/a4.49M1.03M8.33M6.97M
EPS (Basic)n/a-$104.35-$4718.84-$62.23-$136.64n/an/a-$7.74-$24.14-$4.74-$7.98